- Home
- IONS vs BCO Comparison
IONS vs BCO Comparison
Compare IONS & BCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BCO
- Stock Information
- Founded
- IONS 1989
- BCO 1859
- Country
- IONS United States
- BCO United States
- Employees
- IONS N/A
- BCO N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BCO Oil Refining/Marketing
- Sector
- IONS Health Care
- BCO Consumer Discretionary
- Exchange
- IONS Nasdaq
- BCO Nasdaq
- Market Cap
- IONS 4.6B
- BCO 3.7B
- IPO Year
- IONS 1991
- BCO N/A
- Fundamental
- Price
- IONS $28.40
- BCO $87.54
- Analyst Decision
- IONS Buy
- BCO Strong Buy
- Analyst Count
- IONS 18
- BCO 2
- Target Price
- IONS $57.00
- BCO $138.00
- AVG Volume (30 Days)
- IONS 2.0M
- BCO 427.5K
- Earning Date
- IONS 04-30-2025
- BCO 05-07-2025
- Dividend Yield
- IONS N/A
- BCO 1.11%
- EPS Growth
- IONS N/A
- BCO 94.75
- EPS
- IONS N/A
- BCO 3.63
- Revenue
- IONS $705,138,000.00
- BCO $5,011,900,000.00
- Revenue This Year
- IONS N/A
- BCO $0.70
- Revenue Next Year
- IONS $25.80
- BCO $4.60
- P/E Ratio
- IONS N/A
- BCO $24.25
- Revenue Growth
- IONS N/A
- BCO 2.82
- 52 Week Low
- IONS $23.95
- BCO $80.21
- 52 Week High
- IONS $52.34
- BCO $115.91
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- BCO 51.12
- Support Level
- IONS $27.57
- BCO $85.23
- Resistance Level
- IONS $29.04
- BCO $88.35
- Average True Range (ATR)
- IONS 1.79
- BCO 3.65
- MACD
- IONS 0.12
- BCO 0.32
- Stochastic Oscillator
- IONS 68.15
- BCO 69.41
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About BCO Brinks Company (The)
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.